All Posts

2024 was a remarkable year for cell and gene therapies (CGT) with the FDA approving nine innovative products. Read more below about these approved CGT therapies and new indications.

The following table provides info on the companies discussed in this article, including EV, short interest, current top biopharma-hedge fund holdings, and BPIQ portfolio holding percentages.

We identified 5 stocks that are likely to move big on cancer readouts this Q1 2025. We classified these as either Big Mover or Suspected Big Mover catalysts depending on stock options volatility data. We highlight 5 of these catalysts in the graphics below. 👇   $ARVN Vepdegestrant (ARV-471) / Metastatic Breast Cancer / Phase 3 » Phase 3 VERITAC-2 trial designed to position vepdegestrant as a backbone ER-targeting therapy in BCA. » Ph2 VERITAC had favorable tolerability at bo

The 43rd Annual J.P. Morgan Health Care Conference  is taking place in San Francisco, CA from January 13-16, 2025 .

The 43rd Annual J.P. Morgan Health Care Conference  is taking place in San Francisco, CA from January 13-16, 2025 . "This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community." ( https://www.jpmorgan.com/about-us/events-conferences/health-care-conference ) Many of the smid-cap biopharm

We’re always excited to find bio/pharma companies nearing their therapeutic product launch! These 4 companies have FDA final approval decision (PDUFA) dates before the end of January: Atara Biotherapeutics (NASDAQ: ATRA ) Drug/Therapy: Tab-cel (tabelecleucel) Allogeneic T-cell immunotherapy Indication: Post-Transplant Lymphoproliferative Disease (PTLD) PDUFA date: January 15, 2025 BLA with priority review Biogen (NASDAQ: BIIB ) Drug/Therapy: Leqembi (Lecanemab) IV Maintenance

We’re always excited to find bio/pharma companies nearing their therapeutic product launch!

This post provides some ideas on how to Use BPIQ's Hedge Fund Data And Model Portfolios to Beat the Major Biotech ETFs. 1) Use public data on holdings of top biopharma-focused hedge funds (BFHFs) to improve your chances of success in investing in this sector (FN^1) Focus on biopharma stocks held by at least 1 BHFH Our   hedge fund screener tool  makes it easy for you to determine how many BFHFs hold any ticker 2) Use holdings of our BPIQ portfolios as part of your biopharma s

This post provides some ideas on how to Use BPIQ's Hedge Fund Data And Model Portfolios to Beat the Major Biotech ETFs.

TAKE HOME MESSAGE: